drugset / Trial / NCT00865761

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

NCT00865761

Phase 1 Completed 40 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended-release tablet) in healthy adult volunteers administrated under fasting conditions.

Timeline

Start
2005-09
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule 3 mg Oral

Indications

No indication recorded.